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Abstract: Background: A disequilibrium of the gut microbial community has been closely associated
with systemic inflammation and metabolic syndromes including type 2 diabetes. While low fibre and
high fat diets may lead to dysbiosis of the gut microbiome as a result of the loss of useful microbes,
it has been reported that a high fibre diet may prevent the fermentation of protein and may promote
eubiosis of gut microbiota. Aim: This review aims to evaluate the effect of dietary fibre (DF) on gut
microbiota, lipid profile, and inflammatory markers in patients with type 2 diabetes. Methods: The
PRISMA framework was relied on to conduct this systematic review and meta-analysis. Searches were
carried out using electronic databases and reference list of articles. Results: Eleven studies were included
in the systematic review, while ten studies were included in the meta-analysis. The findings revealed five
distinct areas including the effects of DF on (a) gut microbiota (122 participants); (b) lipopolysaccharides
(LPS, 79 participants) and lipopolysaccharides binding protein (LBP, 81 participants); (c) lipid profile;
(d) inflammatory markers; and (e) body mass index (BMI, 319 participants). The relative abundance of
Bifidobacterium increased by 0.73 (95% CI: 0.57, 0.89) in the DF group in contrast to the control (p < 0.05).
With respect to LPS, the level was lower in the DF group than the control and the difference was significant
(p < 0.05). The standardised mean difference for LPS was −0.45 (95% CI: −0.90, −0.01) although the
difference between the two groups in relation to LBP was not significant (p = 0.08) and the mean difference
was 0.92 (95% CI: −0.12, 1.95). While there was a decrease of −1.05 (95% CI: −2.07, −0.02) with respect to
total cholesterol (356 participants) in the DF group as compared with the control (p < 0.05), both groups
were not significantly different (p > 0.05) in the other lipid parameters. The difference between the groups
was significant (p < 0.05) in relation to C-reactive protein, and the mean difference was 0.43 (95% CI: 0.02,
0.84). This could be due to the short duration of the included studies and differences in participants’
diets including the amount of dietary fibre supplements. However, the groups were not significantly
different (p > 0.05) with respect to the other inflammatory markers. The meta-analysis of the BMI showed
that the DF group decreased by −0.57 (95% CI: −1.02, −0.12) as compared with the control and this
was significant (p < 0.01). Conclusion: DF significantly (p < 0.05) increased the relative abundance of
Bifidobacterium and significantly decreased (p < 0.05) LPS, total cholesterol, and BMI as compared with
the control. However, DF did not seem to have an effect that was significant on LBP, triglyceride, HDL
cholesterol, LDL cholesterol, IL-6, TNF-α, adiponectin, and leptin. These findings have implications
for public health in relation to the use of dietary fibre in nutritional interventions and as strategies for
managing type 2 diabetes.
Keywords: type 2 diabetes; lipid profile; gut microbiota; inflammatory markers; body mass index;
lipopolysaccharide; dietary fibre
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1. Introduction
A disequilibrium of the gut microbial community has been closely associated with
systemic inflammation and metabolic syndromes [1,2]. There is evidence that dysbiosis
of the gut microbiome has an effect on the pathogenesis of type 2 diabetes as it regulates
inflammatory markers, interacts with constituents of the diet, modulates the permeability
of the gut, as well as glucose and lipid metabolism, sensitivity of insulin, and balance
of energy [3–5]. The disruption of microbial eubiosis could be due to the quality of
the diets, especially high fat diets and those that are high in sugar and low in dietary
fibre [6]. For example, Western-style diets, which are low in dietary fibre and other
microbiota-accessible carbohydrates, may contribute to a reduction in microbial diversity
and could lead to the depletion of specific bacterial taxa in the digestive ecosystem [6,7].
This process may cause microbial dysbiosis or changes in the profile of gut microbiota
which could impair the integrity of the wall of the intestine and cause gut permeability,
thus, enabling the translocation of toxins from the gut lumen to the systemic circulation [4].
The fermentation of dietary fibres by gut bacteria produces primarily short-chain fatty
acids (SCFAs) including propionic, butyric, and acetic acids, hence, dysbiosis may lead to
significant differences in the concentration of SCFAs in the intestines, of which a deficiency
has been associated with type 2 diabetes [8,9]. The composition of the gut microbiota and
interactions between the different species of microbes influence the type and amount of
SCFAs including butyric, acetic, and propionic acid. In this regard, a low intake of dietary
fibre may cause reduced production of SCFAs and lead to the utilisation of substrates that
are less favourable, such as proteins and fat, by the gut microbiome and the production
of potentially detrimental metabolites including lipopolysaccharide (LPS), a metabolic
endotoxemia often associated with microbiota dysbiosis [6,10,11].
An increase in the permeability of the mucosa wall of the intestine and the movement
of LPS through the epithelium can elicit inflammation and lead to insulin resistance and
development of type 2 diabetes [10]. In particular, the endotoxemia cN cause low-grade
inflammation and oxidative stress which may cause insulin resistance, beta cell dysfunction,
hyperglycemia, hyperlipidemia, and obesity [4]. A high level of endotoxemia has been
found to increase the concentrations of tumour necrosis factor α (TNF-α) and interleukin 6
(IL-6) and the promotion of insulin resistance [12].
Although some gut microbes and their products such as lipopolysaccharides promote
metabolic endotoxemia and low-grade inflammation, others including Roseburia intestinalis,
Bacteroides fragilis, Akkermansia muciniphila, and Lactobacillus plantarum may contribute to
the improvement of glucose metabolism by stimulating anti-inflammatory cytokines and
chemokines [3]. The effect of type 2 diabetes can be profound in terms of its acute and
chronic complications and with significant costs to health services around the world.
1.1. Description of the Intervention
Dietary fibres are carbohydrate polymers that are not digested or absorbed in the
small intestine and are usually fermented in the colon resulting in the production of SCFAs,
some of which may be used as sources of energy [13].
Dietary fibres include non-starch polysaccharides (NSP), which are constituents of
plant cell wall and include cellulose, hemicelluloses, pectins, gums, mucilages, and beta-
glucans, as well as other components such as lignin which are related to carbohydrates
that are non-digestible in cell walls of plants [13]. NSP can be further divided into (a)
soluble fibres, such as those from oats, psyllium, pectin, and guar gum, which can have
an impact on glucose and lipid absorption [14] and (b) insoluble fibres, which are slowly
or not completely fermented in the large intestine and have a significant effect on bowel
habits [13]. Furthermore, non-digestible oligosaccharides including fructo-oligosaccharides
and gluco-oligosaccharides have been shown to influence abundance and diversity of gut
microbiota [14].
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1.2. How the Intervention Might Work
Aliasgharzadeh et al. [5] demonstrated in their study that an imbalance in the intestinal
microbiota was a risk factor for type 2 diabetes. This was based on the understanding
that changes in the ratio of gut microbiota can cause loss of integrity of the intestinal
mucosal barrier and lead to bacteria translocation [10]. In addition, the disruption of
intestinal barrier increases intestinal mucosal permeability, allowing the translocation of
LPS, a metabolic endotoxemia [10]. Thus, microbial dysbiosis could cause an increase
in inflammatory activation via promotion of an immune response to LPS and this may
contribute to insulin resistance and type 2 diabetes [10]. The role of NSP in human
health has been demonstrated by its improvement in the composition and metabolic
products of the gut microbiota, including increasing the abundance of health-promoting
bacteria and the production of SCFAs [15,16]. The SCFAs produced by the fermentation of
polysaccharides have been shown to have a significant effect in improving glycometabolism-
related diseases [15,17]. Furthermore, it has been suggested that the modulation of specific
bacteria that is related to the dysregulation of glucose metabolism by dietary fibre may be an
effective method of promoting glucose homeostasis and improving lipid profile [15,18,19].
1.3. Why It Is Important to do This Review
In our previous review [20], we found that dietary fibre significantly improved the
relative abundance of Bifidobacterium, total SCFAs, and glycated haemoglobin. However,
the findings did not demonstrate any significant impact of dietary fibre on fasting blood
glucose, homeostatic model assessment of insulin resistance, acetate, propionate, butyrate,
and adverse events. Therefore, the current review is a follow-up to the previous review
and focuses on the role of dietary fibre on lipid profile and inflammatory parameters.
Our understanding of gut microbiome will no doubt promote the study of dietary fibre
and its effect on human health and nutrition [21,22]. In addition, new knowledge on the
modulation of gut microbiota by dietary fibre is essential for developing effective strategies
to improve human health and to manag microbiota-related diseases [21]. This is particularly
significant as most microbiome-associated pathologies such as type 2 diabetes are increasing
globally [6,8]. While there is evidence that a high fat diet may be involved in the disruption
of gut microbiota symbiosis resulting from the loss of useful microbes [6,23,24], it has also
been revealed that a high fibre diet may prevent the fermentation of protein and promote
gut microbial eubiosis [6].
A complete understanding of how the communities of microbes and specific bacteria
cause, respond to, or contribute to diseases such as type 2 diabetes is not fully understood
and continues to evolve [9]. On the one hand, according to Mitchell et al. [11], an increased
level of lipopolysaccharide, which is associated with microbiota dysbiosis, has been im-
plicated in conditions such as type 2 diabetes and cardiovascular disease. On the other
hand, Ebrahimzadeh Leylabadlo et al. [8] noted that the effect of lipopolysaccharide con-
centrations on glucose and lipid metabolism in humans has not been studied extensively.
Furthermore, reviews conducted previously have focused only on the effect of whole diet
and/or lifestyle interventions [25] or probiotics [8] on gut microbiota in patients with type
2 diabetes.
1.4. Aim
The aim of this review is to examine the effect of dietary fibre on gut microbiota, lipid
profile, and inflammatory markers in patients with type 2 diabetes.
2. Methods
The preferred reporting items for systematic review and meta-Analysis (PRISMA) [26]
was the framework used for this review.
2.1. Types of Studies
The studies included were randomised controlled trials.
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2.2. Types of Participants
People with type 2 diabetes were the participants included in this review.
2.3. Types of Interventions
Dietary fibre including microbiotic diet was the intervention.
2.4. Types of Outcome Measures
The outcome measures of interest included the following:
• The relative abundance of gut microbiota (genera only) (Bifidobacterium);
• Lipopolysaccharides and lipopolysaccharides binding protein;
• Lipid profile, i.e., high density lipoprotein (HDL) cholesterol, total cholesterol, low
density lipoprotein (LDL) cholesterol, triglycerides;
• Inflammatory markers, i.e., high sensitivity C-reactive protein (hsCRP), interleukin 6
(IL-6), tumour necrosis factor α (TNF-α), adeponectin, and leptin;
• Body mass index (BMI).
2.5. Search Methods for Identification of Studies
Electronic databases including EBSCO-host that includes Health Sciences Research
Databases (encompassing MEDLINE, Academic Search Premier, APA PsycInfo, Psychology
and Behavioral Sciences Collection, APA PsycArticles databases, and CINAHL Plus with
Full Text), EMBASE, Google Scholar, and the reference lists of articles were searched for
relevant articles. A population, intervention, outcome and study (PICOS) design was
the framework used for the searches which were conducted from database inception to 3
March 2021 (Table 1). Synonyms and medical subject headings (MesH) were used as search
terms, and these were combined using Boolean operators (OR/AND). Two researchers
(O.O. and O.O.O.) independently conducted the searches and were cross-checked by N.Z.
and X.W. Differences were resolved through discussion and consensus. Records of searches
from databases were transferred to EndNote (Analytics, Philadelphia, PA, USA) and the
duplicates were removed.
Table 1. Search terms and search strategy (adapted from Ojo et al. [20]).
Population Interventions Outcome Design of Study Search TermsCombined
Patients with diabetes Dietary fibre Gut microbiota Randomised controlled trial




















#1 Controlled clinical trial OR
Randomised controlled trial
OR randomly OR trial
randomised OR placebo OR
groups OR drug therapy
#2 “Animals” NOT “Humans”





2.6. Data Collection and Analysis
2.6.1. Selection of Studies
Inclusion and exclusion criteria were used to select the studies included and those
excluded based on a PRISMA flow chart (Figure 1).
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Figure 1. PRISMA flow chart of studies included.
i l i criteria included the following: Only randomised controlled studies in-
volving patients with ype 2 diabetes were included in this review. Studies w th participants
aged 18 years or over and with outcomes involving gut microbiota, lip polysaccharide,
lipid profiles, inflammatory par meters, and anthropometric measurements were also
included in this rev ew.
i rit ria i cluded the fo lowing: Studies involving patients with type
1 diab tes, prediabetes, or gestational diabetes, and participants ag d below 18 yea s
were excluded from this review. Animal studies and those involving probiotics were
also excluded.
2.6.2. Data Extraction and Management
One researcher (O.O.) extracted the data from the selected articles, which was cross-
checked by the other three researchers (O.O.O., N.Z., and X.W.). Changes from baseline and
final values in the intervention group were compared to the control. Web Plot Digitizer [27]
was used to extract data from graphs in the Medina-Vera et al. [28] and Pedersen et al. [29]
studies. The units of measurements for lipid parameters were converted to mmol/L,
while median and 1st and 3rd quartiles were converted to means and standard deviations,
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respectively, using an Excel table for estimating mean and standard deviation from median
and quartiles.
2.6.3. Assessment of Risk of Bias in Included Studies
Two researchers (O.O. and O.O.O.) used the domain-based risk assessment tool [30]
to evaluate the risk of bias of the studies included by and this was cross-checked by the
two other researchers (N.Z. and X.W.). The domains assessed were allocation concealment,
the random sequence generation, blinding of outcome assessment, blinding of participants
and personnel, selective reporting, incomplete outcome data, and other biases [30]. The
Review Manager 5.3 software (Copenhagen, Denmark) [31] was used to carry out the risk
assessment. Furthermore, the quality of the evidence was assessed by means of the Critical
Appraisal Skills Programme [32] checklist for randomised controlled trials.
2.6.4. Data Analysis
The Review Manager (RevMan) 5.3 software [31] was used to carry out the meta-
analysis. One study at a time was removed from the meta-analysis to facilitate the sensitiv-
ity analysis, and thus determine the level of consistency of the results. Heterogeneity of
studies was measured by I2 statistic [30] and expressed as percentage. The random effects
model was used for meta-analysis in data with high heterogeneity, while the fixed effects
model was used in data with low to medium heterogeneity. For lipopolysaccharides, the
standardised mean difference was used for the analysis due to differences in the units of
measurements of the included studies. Furthermore, both change scores (change from
baseline) were combined with final scores in the meta-analysis [30].
2.6.5. Effect Size
The results of the meta-analysis are presented as forest plots, while the overall effect
of the intervention was based on p < 0.05 with respect to statistical significance.
3. Results
There were eleven studies included in the systematic review, while the meta-analysis
had ten studies (Figure 1). The type of study, details of sample size, the mean age/range,
the aims of studies, interventions, and results of the included studies are outlined in Table 2.
While one study each was conducted in Belgium [33], Canada [34], China [35], Japan [36],
Mexico [28], Norway [37], and UK [29], four studies were carried out in Italy [38–41]. All
the studies included were randomised controlled trials.
Risk of Bias of Included Studies
With respect to incomplete outcome data and selective reporting, all the studies
demonstrated a low risk of bias (Figure 2a,b). However, some studies showed an unclear
risk of bias in relation to random sequence generation, allocation concealment, and blinding
of outcome assessment, while one study [40] showed a high risk of bias in relation to
blinding of participants and personnel (Figure 2a,b).
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Table 2. The description and characteristics of included studies (adapted from Ojo et al. [20]).
Authors/Country of
Study Type of Study Details of Sample
Mean Age/Range
(Years) Aim Type of Interventions Findings
Birkeland et al. [37],
Norway RCT n = 25 63.1: 41–73
To examine the effect of
inulin-type fructans on
faecal microbiota and







A 4 week washout
separated 6 weeks of
treatment
The results found a moderate
potential of inulin-type fructans to
promote the composition of gut
microbiota and to increase microbial
fermentation in T2D.
Candela et al. [38],
Italy RCT
Ma-Pi 2 diet (n = 21),






Ma-Pi 2 diet or a
control diet
Macrobiotic Ma-Pi 2 diet
rich in fibre versus
control diet.
A 21-day treatment
The Ma-Pi 2 diet was effective in
alleviating the increase of possible
proinflammatory groups, in the gut
ecosystem, but not the control diet.
It demonstrated the possibility of
reversing proinflammatory
dysbiosis in patients with T2D and
its effectiveness in improving
metabolic control.
Gonai et al. [36],
Japan RCT
GOS (n = 27),
placebo (n = 25)
GOS (55 ± 11)
Placebo (54 ± 12)










restored in patients with diabetes
after consuming GOS. On the other
hand, there was no improvement in
LBP and glucose tolerance during
this short period of trial. It was
shown that GOS could mitigate
dysbiosis in patients with diabetes,
and continuous intake of GOS may
be useful in managing type
2 diabetes.




prebiotic n = 24, placebo
n = 23)
Age ranged from 18 to
65 years.
To explore the effect of
inulin supplementation
with metformin in obese





assigned to the prebiotic
or placebo arm
A 3-month treatment
A large increase in Bifidobacterium
may be due to inulin intake rather
than a driver of prebiotic-linked
biological outcomes.
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Table 2. Cont.
Authors/Country of
Study Type of Study Details of Sample
Mean Age/Range
(Years) Aim Type of Interventions Findings
Medina-Vera et al. [28],
Mexico RCT
T2D (n = 81)
Final Group numbers
analysed:
DF (n = 28),
placebo (n = 25)
DP (50.4 ± 8.7)
Placebo (49.8 ± 10.6)
To examine the role of
dietary intervention
(functional food-based)
on faecal microbiota and
biochemical parameters
in patients with type
2 diabetes.
A dietary portfolio (DP)
versus placebo
A 3-month treatment
The long term use of diets that are
high in fibre, rich in polyphenol and
vegetable-protein-based provide
advantages in enhancing the faecal
microbiota composition and may be
used as therapies for managing
dyslipidaemia and inflammation.
Pedersen et al. [29],
UK RCT
GOS (n = 14),
placebo (n = 15)
GOS (56.7 ± 1.6)
Placebo (58.1 ± 1.7)









As compared with the placebo,
supplementation with prebiotic
fibre did not appear to show any
significant impact on clinical
outcomes or bacterial abundances.
Reimer et al. [34],
Canada RCT
PGX® (n = 147),
placebo (n = 143)
PGX® (56.2 ± 8.6)
Placebo (53.4 ± 9.9)
To evaluate the adjunct
effect of the soluble





PGX® may be a useful adjunct to
weight loss programs in patients
with type 2 diabetes based on
improvements in other metabolic
parameters.
Soare et al. [39],
Italy RCT
Ma-Pi 2 diet (n = 25),





The effect of various
dietary methods (the







Ma-Pi 2 diet versus
control diet
A 21-day treatment
There was significantly better
improvements in metabolic control
in patients with type 2 diabetes
following the intervention with a
short-term Ma-Pi 2 diet.
Soare et al. [40],
Italy RCT
Ma-Pi 2 diet (n = 25),
control diet (n = 26)
Age ranged from 40 to
75 years
To investigate the effects
of macrobiotic Ma-Pi 2





This was a post hoc
analysis of the MADIAB
trial
A 21-day RCT.
As compared with the baseline data,
it was found that Ma-Pi 2 diet was a
safe dietary method of reducing
levels of inflammatory markers, in
the short term.
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Table 2. Cont.
Authors/Country of
Study Type of Study Details of Sample
Mean Age/Range
(Years) Aim Type of Interventions Findings
Soare et al. [41],
Italy RCT
Ma-Pi 2 diet (n = 17),
control diet (n = 23)
Ma-Pi 2 diet (65 ± 8.89)







and into everyday life.
Fibre-rich macrobiotic




There was higher percentage
reduction in body weight and a
higher percentage increase in LDL
cholesterol in the Ma-Pi diet.
Furthermore, all the participants’
total and LDL cholesterol levels
were within recommended levels.







Control (59.7 ± 6.0)
To assess the effect of gut
microbiota and its role in
glucose homeostasis in
patients with type 2
diabetes.
High dietary fibre versus
usual care
A 84 days study
Dietary fibre was effective in
promoting a group of
SCFA-producing strains, while most
of the other potential producers
were either reduced or unchanged
in patients with type 2 diabetes.
Abbreviations: DP (dietary portfolio); GOS (galacto-oligosaccharide); LBP (lipopolysaccharide binding protein); LDL (low density lipoprotein) cholesterol; Ma-Pi 2 (macrobiotic diet); PGX® (PolyGlycopleX®);
SCFA (short chain fatty acid); T2D (type 2 diabetes); RCT (randomised Controlled Trial).
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participants); (c) lipid profile, (d) infla matory markers, and (e) body mass index
(319 participants).
Gut Microbiota
edina-Vera et al. [28] found that the consu ption of a diet rich in fibre increased
the levels of Faecalibacteriu prausnitzii and Akker ansia uciniphil hich are t o bacterial
species that have been known to have anti-inflammatory effects. The high fibre diet also
promoted the abundance of Bifidobactrium longum. Furthermore, Reimer et al. [34] found
that there was a significant increase in the dietary fibre group with respect to the relative
abundance of Collinsella, Parabacteroides, and Roseburia as compared with the control. The
effects of dietary fibre on gut microbiota have previously been described in our earlier
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review [20]. In the current meta-analysis of the relative abundance of Bifidobacterium, there
was an increase of 0.73 (95% CI: 0.57, 0.89) in the dietary fibre group as compared with the
control (p < 0.05) (Figure 3).
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(b) Lipopolysaccharide (LPS) and Lipopolysaccharide Binding Protein (LBP)
, fi
l l of lipopolysa charide (p < .05) in the dietary fibre group as compared with the
control, with a st n ar ised mean reduction of −0.45 (95% CI: −0.90, −0.01) (Figure 4a).
However, there was no sig ificant difference (p = 0.08) between the dietary fibre group as
compared with the control in relation to LBP with a mean difference of 0.92 (95 I: 0.12,
1.95) (Figure 4b).
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(c) Lipid Profile
ccording to edina- era et al. [28], there ere significant reductions in total choes-
terol, LDL cholesterol, free fatty acids, and triglyc rides in the dietary fibre group as
compared with the control. Similarly, Reimer et al. [34] noted that the reductions in LDL
cholesterol at 16 and 26 weeks in the dietary fibre group were significant as compared
with the baseline data. There were significant reductions in total cholesterol and LDL
cholesterol [39] in the Ma-Pi 2 diet group as compared with the control, while a study by
Soare et al. [41] found no significant differences in relation to total and LDL cholesterol
between the two groups.
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The meta-analyses of the lipid parameters are shown in Figure 5a–d. While there was a
decrease of −1.05 (95% CI: −2.07, −0.02) with respect to total cholesterol (356 participants)
in the dietary fibre group as compared with the control (p < 0.05) (Figure 5a), the two groups
were not significantly different (p > 0.05) in relation to triglyceride (317 participants), high
density lipoprotein cholesterol (355 participants), and LDL cholesterol (408 participants)
(p > 0.05) (Figure 5b–d).
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Medina-Vera et al. [28] noted that there were significant reductions in the levels of
C-reactive protein in the dietary fibre group as compared with the control. The meta-
analysis showed that differences between the two groups was significant (p < 0.05) in
relation to C-reactive protein, with a mean difference of 0.43 (95% CI: 0.02, 0.84) (Figure 6a).
However, there were no significant differences (p > 0.05) between the two groups with
respect to interleukin 6 (IL-6), tumour necrosis factor α (TNF-α), adiponectin, and leptin
(Figure 6b–e).





Figure 5. The effect of dietary fibre on (a) total cholesterol (mmol/L); (b) triglyceride (mmol/L); (c) HDL cholesterol 
(mmol/L); (d) LDL cholesterol (mmol/L). 
(d) Inflammatory Markers 
Medina-Vera et al. [28] noted that there were significant uctions in the levels of C-
reactive protein in the dietary fibre group as compared with the control. The meta-analysis 
showed that differences between the two groups was significant (p < 0.05) in relation to 
C-reactive protein, with a mean difference of 0.43 (95% CI: 0.02, 0.84) (Figure 6a). How-
ever, there were no significant differences (p > 0.05) between the two groups with respect 















Figure 6. The effect of dietary fibre on (a) C-reactive protein (mg/L); (b) IL-6 (pg/mL); (c) TNF-α (pg/mL); (d) adiponectin 
(µg/mL); (e) leptin (ng/mL). 
(e) Body Mass Index (BMI) 
Reimer et al. [34] observed that, following the intervention, there was significant de-
crease in body weight in the dietary fibre group as compared with baseline. In addition, 
Soare et al. [39] found that BMI in the Ma-Pi diet group was significantly lower than that 
in the control diet group. 
The meta-analysis of the BMI revealed that the dietary fibre group decreased by −0.57 
(95% CI: −1.02, −0.12) as compared with the control group and the difference was signifi-
cant (p < 0.01) (Figure 7). 
 
Figure 7. The effect of dietary fibre on body mass index (kg/m2). 
4. Discussion 
The results of this systematic review and meta-analysis have shown that dietary fibre 
was effective in significantly increasing (p < 0.05) the relative abundance of Bifidobacterium, 
decreasing lipopolysaccharide, total cholesterol, and body mass index as compared with 
the control. The dietary fibre group also showed a significant increase in the level of C-
reactive protein. However, differences between both groups were not significant (p > 0.05) 
in relation to LBP, triglyceride, HDL cholesterol, LDL cholesterol, IL-6, TNF-α, adiponec-
tin, and leptin. 
The findings of this review confirm some results of previous studies and reviews in 
relation to the role of diet in modulating gut microbiota, lipid profile, and inflammatory 
Figure 6. The effect of dietary fibre on (a) C-reactive protein (mg/L); (b) IL-6 (pg/mL); (c) TNF-α (pg/mL); (d) adiponectin
(µg/mL); (e) leptin (ng/mL).
Nutrients 2021, 13, 1805 14 of 18
(e) Body Mass Index (BMI)
Reimer et al. [34] observed that, following the intervention, there was significant
decrease in body weight in the dietary fibre group as compared with baseline. In addition,
Soare et al. [39] found that BMI in the Ma-Pi diet group was significantly lower than that in
the control diet group.
The meta-analysis of the BMI revealed that the dietary fibre group decreased by
−0.57 (95% CI: −1.02, −0.12) as compared with the control group and the difference was
significant (p < 0.01) (Figure 7).







Figure 6. The effect of dietary fibre on (a) C-reactive protein (mg/L); (b) IL-6 (pg/mL); (c) TNF-α (pg/mL); (d) adiponectin 
(µg/mL); (e) leptin (ng/mL). 
(e) Body Mass Index (BMI) 
Reimer et al. [34] observed that, following the intervention, there was significant de-
crease in body weight in the dietary fibre group as compared with baseline. In addition, 
Soare et al. [39] found that BMI in the Ma-Pi diet group was significantly lower than that 
in the control diet group. 
The meta-analysis of the BMI revealed that the dietary fibre group decreased by −0.57 
(95% CI: −1.02, −0.12) as compared with the control group and the difference was signifi-
cant (p < 0.01) (Figure 7). 
 
Figure 7. The effect of dietary fibre on body mass index (kg/m2). 
4. Discussion 
The results of this systematic review and meta-analysis have shown that dietary fibre 
was effective in significantly increasing (p < 0.05) the relative abundance of Bifidobacterium, 
decreasing lipopolysaccharide, total cholesterol, and body mass index as compared with 
the control. The dietary fibre group also showed a significant increase in the level of C-
reactive protein. However, differences between both groups were not significant (p > 0.05) 
in relation to LBP, triglyceride, HDL cholesterol, LDL cholesterol, IL-6, TNF-α, adiponec-
tin, and leptin. 
The findings of this review confirm some results of previous studies and reviews in 
relation to the role of diet in modulating gut microbiota, lipid profile, and inflammatory 
Figure 7. The ef ect of dietary fibre on body mas index (kg/
.
lt f t i t ti i t - l i t t i t fi
s ff ti i si ifi tl i r si ( . ) t r l ti f ifi cteri ,
ecre si li l s cc ri e, t t l c lester l, ss i e s c re it
t e co trol. e ietary fibre gro also s o e a sig ifica t i crease i t e level of -
reactive protein. o ever, differences bet een both groups ere not significant (p > 0.05)
in relation to LBP, triglyceride, HDL cholesterol, LDL cholesterol, IL-6, TNF-α, adiponectin,
and leptin.
The findings of this review confirm some results of previous studies and reviews in
relation to the role of diet in modulating gut microbiota, lipid profile, and inflammatory
markers. They also provide us with a better understanding of the effect of nutritional
interventions in managing microbiota-associated diseases such as type 2 diabetes. For
example, Haghighatdoost et al. [42] found that the changes in serum levels of IL-6 and
TNF-α in the intervention group (resistant starch) as compared with the control group were
not significant, which is similar to the current findings. The authors also noted that resistant
starch (RS2) that reaches the large intestine in an undigested form may be fermented by
gut microbiota and that this can improve the growth of some bacteria families including
Bifidobacteriaceae and Lactobacilli, which can reduce inflammation. Our results align with
that observation, as we found that the relative abundance of Bifidobacterium significantly
increased in the dietary fibre group as compared with the control and that this may have
also influenced the significant reduction in the level of LPS in the dietary fibre group.
According to Medina-Vera et al. [28], the reduction in the concentration of LPS by
−65% in the intervention group as compared with −52% in the control group showed
that dietary interventions could be effective in reducing metabolic endotoxaemia. Gonai
et al. [36] noted that, while Bifidobacteriaceae was significantly restored in patients with
diabetes after consumption of dietary fibre, LBP did not improve during the short-term
trial period.
The high level of LPS in the control group may be due to the imbalance of gut micro-
biota resulting from the lower dietary fibre content [15]. There is evidence that microbial
dysbiosis can lead to a loss of integrity of the intestinal wall which could enable the translo-
cation of LPS through the intestinal epithelium, eliciting an inflammatory response and
causing oxidative stress, beta cell destruction, and/or insulin resistance [1,4,10]. In addition,
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high levels of endotoxemia have been shown to increase levels of TNF-α, IL-6, and insulin
resistance [12]. According to Haghighatdoost et al. [42], these proinflammatory factors play
significant roles in insulin resistance, lipid disorders, and increased oxidative stress.
However, an inflammatory response resulting from LPS is mediated by lipopolysac-
charide binding protein (LBP) which is produced mainly in the liver [43,44]. It has been
reported that LBP levels increase during infection and are usually greater in the presence
of markers of inflammation [43,45]. This would appear to align with the findings of the
present review, where there were no significant differences (p > 0.05) between the dietary
fibre group and the control with respect to LBP and proinflammatory markers, except for
C-reactive protein. The significantly higher level of C-reactive protein in the intervention
group as compared with the control in the current review may be due to the length of the
studies included for C-reactive protein, which were of a relatively short duration (ranging
from 21 days to 3 months), and thus not long enough to exert its full effect [36,42]. It
could also be due to differences in the participants’ diets including the amount of dietary
fibre supplements.
Gut microbiota have been shown to produce short chain fatty acids including propi-
onic, butyric, and acetic acids from the fermentation of the dietary fibre which can lead to
improvement in glycometabolism and regulation of the host immune system [6,15,20].
The significantly lower level (p < 0.05) of total cholesterol and body mass index
found in the dietary fibre group as compared with the control in this review could be
ascribed to the effect of the dietary fibre. According to the Scientific Advisory Committee
on Nutrition [14], there is sufficient evidence to confirm the association between the
compounds that are identified as NSP and colonic function such as stool weight/mass
and transit time, and between the compounds that are recognised as soluble fibre and the
lowering of total cholesterol and LDL cholesterol. Medina-Vera et al. [28] noted that long-
term use of diets high in fibre, rich in polyphenol, and vegetable-protein-based diets could
provide beneficial effects in enhancing faecal microbial composition and could provide
potential benefits for improving glycamia, dyslipidaemia, and inflammation.
The increased concentration of butyrate, a SCFA, has also been reported to reduce
the production of glucose in the liver, improve glucose homeostasis, and reduce body
weight [8]. Furthermore, SCFAs have been shown to modulate the metabolism of glucose
and lipid through the activation of SCFA receptors on the liver and adipose tissue [8,46]. A
weight loss of 5–10% has been found to be adequate in obtaining significant health benefits
from decreasing comorbidities [47]. In addition, Wing et al. [48] noted that moderate weight
losses from 5 to <10% can improve cardiovascular disease risk factors including glycemia,
blood pressure, triglycerides, and HDL cholesterol, but not with respect to LDL cholesterol
at 1 year, although it was also recognised that larger weight losses had greater benefits.
Limitation of the Review
The number of studies that were included in the meta-analysis of gut microbiota and
some of the metabolites such as LPS, LBP, and inflammatory markers were limited despite
having 10 studies included in the overall meta-analysis. Therefore, the application of the
results in the wider context may be limited.
5. Conclusions
The findings of this review have shown that dietary fibre can significantly (p < 0.05)
increase the relative abundance of Bifidobacterium and significantly decrease (p < 0.05)
lipopolysaccharide, total cholesterol, and body mass index as compared with a control.
However, the results demonstrated that there were no significant (p > 0.05) differences
between the dietary fibre group and a control with respect to LBP, triglyceride, HDL
cholesterol, LDL cholesterol, IL-6, TNF-α, adiponectin, and leptin. These findings have
public health implications in terms of the use of dietary fibre in nutritional interventions
and as strategies for managing type 2 diabetes.
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